Enrique A. Conterno Sells 25,000 Shares of Eli Lilly And Co (LLY) Stock

Share on StockTwits

Eli Lilly And Co (NYSE:LLY) SVP Enrique A. Conterno sold 25,000 shares of the company’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $121.00, for a total value of $3,025,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

NYSE:LLY opened at $122.66 on Thursday. The stock has a market capitalization of $129.94 billion, a P/E ratio of 22.10, a price-to-earnings-growth ratio of 2.47 and a beta of 0.37. The company has a current ratio of 1.91, a quick ratio of 1.53 and a debt-to-equity ratio of 0.83. Eli Lilly And Co has a twelve month low of $74.51 and a twelve month high of $123.33.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.03). The business had revenue of $6.44 billion during the quarter, compared to analyst estimates of $6.28 billion. Eli Lilly And Co had a net margin of 13.16% and a return on equity of 42.55%. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period last year, the business earned $1.14 earnings per share. Equities analysts predict that Eli Lilly And Co will post 5.6 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Investors of record on Friday, February 15th will be paid a $0.645 dividend. The ex-dividend date of this dividend is Thursday, February 14th. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.56. This represents a $2.58 annualized dividend and a yield of 2.10%. Eli Lilly And Co’s dividend payout ratio (DPR) is 46.49%.

Several analysts have recently issued reports on LLY shares. Barclays reissued a “buy” rating and set a $130.00 target price on shares of Eli Lilly And Co in a report on Sunday, January 20th. BMO Capital Markets increased their target price on Eli Lilly And Co from $124.00 to $132.00 and gave the stock an “outperform” rating in a report on Monday, December 24th. They noted that the move was a valuation call. TheStreet raised Eli Lilly And Co from a “c+” rating to a “b+” rating in a report on Tuesday, November 6th. UBS Group started coverage on Eli Lilly And Co in a report on Wednesday, January 23rd. They set a “buy” rating and a $131.00 target price on the stock. Finally, Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $128.00 target price on the stock in a report on Wednesday, November 28th. Eleven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $111.41.

A number of large investors have recently added to or reduced their stakes in the stock. State of Alaska Department of Revenue raised its position in Eli Lilly And Co by 3.3% in the fourth quarter. State of Alaska Department of Revenue now owns 204,487 shares of the company’s stock valued at $23,660,000 after purchasing an additional 6,474 shares during the last quarter. Arizona State Retirement System raised its position in Eli Lilly And Co by 0.8% in the third quarter. Arizona State Retirement System now owns 278,567 shares of the company’s stock valued at $29,893,000 after purchasing an additional 2,174 shares during the last quarter. Waverton Investment Management Ltd raised its position in Eli Lilly And Co by 1.9% in the fourth quarter. Waverton Investment Management Ltd now owns 12,724 shares of the company’s stock valued at $1,472,000 after purchasing an additional 238 shares during the last quarter. Balasa Dinverno & Foltz LLC raised its position in Eli Lilly And Co by 15.9% in the third quarter. Balasa Dinverno & Foltz LLC now owns 3,629 shares of the company’s stock valued at $389,000 after purchasing an additional 499 shares during the last quarter. Finally, Sumitomo Life Insurance Co. raised its position in Eli Lilly And Co by 2.7% in the fourth quarter. Sumitomo Life Insurance Co. now owns 30,683 shares of the company’s stock valued at $3,551,000 after purchasing an additional 800 shares during the last quarter. 75.69% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Enrique A. Conterno Sells 25,000 Shares of Eli Lilly And Co (LLY) Stock” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.tickerreport.com/banking-finance/4168476/enrique-a-conterno-sells-25000-shares-of-eli-lilly-and-co-lly-stock.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Relative Strength Index

Insider Buying and Selling by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

ValuEngine Downgrades Thor Industries  to Strong Sell
ValuEngine Downgrades Thor Industries to Strong Sell
Caesars Entertainment Co.  Expected to Post Quarterly Sales of $2.09 Billion
Caesars Entertainment Co. Expected to Post Quarterly Sales of $2.09 Billion
Fifth Street Asset Management  and Artisan Partners Asset Management  Head-To-Head Review
Fifth Street Asset Management and Artisan Partners Asset Management Head-To-Head Review
Malibu Boats Inc  Given Average Recommendation of “Buy” by Analysts
Malibu Boats Inc Given Average Recommendation of “Buy” by Analysts
Avangrid Inc  Given Consensus Rating of “Hold” by Analysts
Avangrid Inc Given Consensus Rating of “Hold” by Analysts
Hilton Grand Vacations  Receives Outperform Rating from Credit Suisse Group
Hilton Grand Vacations Receives Outperform Rating from Credit Suisse Group


© 2006-2019 Ticker Report